Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion. (November 2021)

• Record Type: Journal Article
• Authors: Goldin, Laurel; Elders, Ty; Werhane, Leslie; Korwek, Kimberly; Poland, Russell; Guy, Jeffrey
• Is Part Of: International journal of infectious diseases. Volume 112(2021)
• Page Start: 73
• Page End: 75
• Publication Date: 2021-11
• Subjects: COVID-19 -- Sars-Co-V-2 -- monoclonal antibody; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2021.09.007
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: SARS-CoV-2 monoclonal antibodies for COVID-19 cause few immediate adverse reactions. Reactions to monoclonal antibody treatment are primarily mild in severity. Most patients who receive this treatment do not have further COVID-19 progression. Abstract: SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a treatment for mild to moderate COVID-19, with favorable outcomes reported in clinical trials and an emergency use authorization granted by the Food and Drug Administration. Real-world data remain limited, however, and thus this analysis presents findings from over 6, 500 outpatient administrations of mAb at facilities affiliated with a large healthcare organization in the United States. Within 48 hours of mAb infusion, 15.6% (1, 043) of patients received a drug that was indicative of a possible reaction to the infusion; the majority of these were mild (e.g., acetaminophen). Approximately 5.2% of patients who received mAb (n=347) had a post-infusion emergency department visit or admission for COVID-19 disease progression. The results of this analysis indicate that patients who receive mAb have a low likelihood of both an immediate negative reaction to the treatment as well as future inpatient admission related to COVID-19 disease progression.